The current global concerns are caused by a new coronavirus strain never found in human body before, belonging to β genus, which is highly infectious and can be transmitted by droplets, contact and aerosols. International Committee on Taxonomy of Viruses entitled it as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes pneumonia named Coronavirus Disease 2019 (COVID-19) by the World Health Organization. Infected patients show symptoms like fever, dry cough and fatigue, often accompanied by shortness of breath and dyspnea, among whom the severe cases reveal severe acute respiratory distress syndrome, septic shock, multifunctional failure, and even died. According to the current research and epidemiological reports, the virus reaches the lower respiratory tract through the upper respiratory tract after the body is infected, and will go through incubation period of normally three to seven days. The number of viruses at different parts or stages varies in that the quantity of corresponding receptors is diverse.

In this public health emergency, the diagnosis has always been the focus of attention. Nucleic acid detection was once considered the gold standard for diagnosis of SARS-CoV-2, but a negative result can not exclude SARS-CoV-2 infection. At present, the conventional method is fluorescence quantitative PCR that is highly limited by experimental conditions, facilities and personnel, and involves many influencing factors, sophisticated operation steps and requires long detection time. With the deepening of the understanding of the disease and the accumulation of diagnosis and treatment experience, in order to further strengthen the early diagnosis and treatment, the detection of SARS-CoV-2 specific antibody and nucleic acid, and the sequence information of virus gene are both adopted as etiological evidences for the diagnosis of suspected cases. According to reports, nucleic acid tests showed positive in feces and urine of patients with COVID-19. After the virus infects human body, the SARS-CoV-2 antigen can be produced in 1-5 days, whose corresponding IgM antibodies can be produced in 5-7 days, and IgG antibody produced in 10-15 days.

Creative Biolabs provides comprehensive SARS-CoV-2 diagnostic test kits for research use, which are specified as 1 test/kit, 10 tests/kit, 100 tests/kit, or 500 tests/kit, etc., to quantitatively test the new coronavirus IgM antibody in human serum samples in vitro to supplement the nucleic acid diagnosis of suspected patients. All of the test kits are applicable for hospitals, clinics and test laboratories to get deployed for businesses, schools, airports, seaports and train stations, etc.

Catalogue
Novel Coronavirus (SARS-CoV-2) IgM/IgG Antibody Detection Kit (Magnetic particle chemiluminescence)
Novel Coronavirus N-protein Detection Kit (ELISA)
Novel Coronavirus (SARS-CoV-2) IgM Antibody Detection Kit (Colloidal gold method)
Novel Coronavirus (SARS-CoV-2) Nucleic Acid Detection Kit (Fluorescent RT-PCR method)
Novel Coronavirus (SARS-CoV-2) Nucleic Acid Detection Kit (Combinatorial Probe-Anchor Synthesis, cPAS)

The immune system is a crucial defense against pathogen invasion that stimulates the specific antibodies to clear virus. In the process of immune response to infection, IgM is the first type to be produced that has low concentration and maintains for a short period of time, which is an indicator of acute infection; while IgG is generated later, with higher concentration and longer hold-up, the positive result of which indicates in the middle, late or previous infection. Therefore, IgM and IgG are of great significance to the monitoring of infection. The corresponding antibody detection technology needs to be adopted in the diagnosis and screening of SARS-CoV-2, making up and improving the deficiency of nucleic acid detection, especially in the diagnosis and exclusion of suspected cases.